TriangleNCT01731886 · OUTCOME
Progression Free Survival (PFS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 4 years
What was measured
PFS is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.
Analysis population: Only patients who achieved at least a partial response (PR) following 4 cycles of induction were included in the analysis.
Groups in this outcome
Arm A: Low-dose Dexamethasone + Stem Cell Transplantation
Subjects will receive the current standard of care treatment. Lenalidomide and dexamethasone for four 28-day cycles followed by stem cell collection and autologous peripheral blood stem cell transplant. After 90 days, start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
Arm B: Low-dose Dexamethasone
Subjects will receive the new treatment that will be compared with the standard of care. Lenalidomide and dexamethasone for eight 28-day cycles. After four cycles your stem cells will be collected (stem cell collection). After an additional four cycles of lenalidomide (a total of 8 cycles), start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses). Only includes subjects who received drug.
| Group | Source count |
|---|---|
| Arm A: Low-dose Dexamethasone + Stem Cell Transplantation | 25 |
| Arm B: Low-dose Dexamethasone | 19 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm A: Low-dose Dexamethasone + Stem Cell Transplantation | 36.0 | Not reported | 17.2 | 54.8 | Not reported |
| Arm B: Low-dose Dexamethasone | 31.6 | Not reported | 10.7 | 52.5 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 17.2
- upper Limit
- 54.8
- value
- 36.0
- group Id
- OG001
- lower Limit
- 10.7
- upper Limit
- 52.5
- value
- 31.6
- denoms
- counts
- group Id
- OG000
- value
- 25
- group Id
- OG001
- value
- 19
- units
- Participants
- description
- PFS is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Subjects will receive the current standard of care treatment. Lenalidomide and dexamethasone for four 28-day cycles followed by stem cell collection and autologous peripheral blood stem cell transplant. After 90 days, start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
- id
- OG000
- title
- Arm A: Low-dose Dexamethasone + Stem Cell Transplantation
- description
- Subjects will receive the new treatment that will be compared with the standard of care. Lenalidomide and dexamethasone for eight 28-day cycles. After four cycles your stem cells will be collected (stem cell collection). After an additional four cycles of lenalidomide (a total of 8 cycles), start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses). Only includes subjects who received drug.
- id
- OG001
- title
- Arm B: Low-dose Dexamethasone
- param Type
- NUMBER
- population Description
- Only patients who achieved at least a partial response (PR) following 4 cycles of induction were included in the analysis.
- reporting Status
- POSTED
- time Frame
- 4 years
- title
- Progression Free Survival (PFS)
- type
- SECONDARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice